Sol-Gel Technologies EBIT

The latest EBIT for SLGL is $-17M as of June 2026. That compares with $14M in the prior-year period — down 227.9% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Sol-Gel Technologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, SLGL's EBIT moved from $14M to $-17M — a 227.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sol-Gel Technologies's operating scale or balance-sheet position.

Against Healthcare companies, SLGL currently prints $-17M for EBIT, while the sector average sits near $99B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Sol-Gel Technologies's growth, margins, and balance sheet.

A EBIT figure of $-17M for SLGL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting SLGL's EBIT ($-17M), review year-over-year change from $14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.